TABLE I.
Demographic and treatment characteristics of patients with metastatic breast cancer receiving nab-paclitaxel
| Variable | Value |
|---|---|
| Patients (n) | 43 |
| Age (years) | |
| Mean | 57.0 |
| Range | 34–74 |
| Receptor status (%) | |
| er-positive | 72.1 |
| pr-positive | 58.1 |
| her2-positive | 16.3 |
| Sites of metastasis (%) | |
| Bone only | 11.6 |
| Liver only | 2.3 |
| Lung only | 4.6 |
| Multiple sites | 81.5 |
| Current line of chemotherapy for advanced disease [median (range)] | 3 (1–6) |
| Previous taxane exposure [n (%)] | 31 (72.1) |
| Adjuvant | 6 (19.35) |
| Metastatic | 23 (74.2) |
| Adjuvant and metastatic | 2 (6.45) |
| Nab-paclitaxel treatment | |
| Schedule [n (%)] | |
| Weekly (qw) | 19 (44.2) |
| Every 3 weeks (q3w) | 20 (46.5) |
| q3w, then switch to qw | 3 (7.0) |
| qw then switch to q3w | 1 (2.3) |
| Mean starting dose (mg) | |
| qw | 222±99.6 |
| q3w | 404±110 |
| Dose reductions (%) | |
| qw | 27.3 |
| q3w | 61.9 |
| Cycles [median (range)] | |
| qw | 12 (1–36) |
| q3w | 5 (2–22) |
| Median duration (months) | |
| qw | 5.1 |
| q3w | 3.0 |
| os for the entire cohort (months) | |
| Median | 11.9 |
| Interquartile range | 7.7–21.8 |
er = estrogen receptor; pr = progesterone receptor; her2 = human epidermal growth factor receptor 2; os = overall survival.